Nigeria’s five listed pharmaceutical manufacturers increased their combined factory and equipment investment to N29.26bn in the first nine months of 2026, as they expand local production and reduce reliance on imported medicines.
The companies, Fidson Healthcare, May & Baker, MeCure Industries, Morrison Industries and Neimeth International Pharmaceuticals, spent N29.26bn on capital projects between January and September, up from N16.20bn recorded in the same period of 2025.
MeCure Industries accounted for the largest share, investing N16.69bn, representing a 66 per cent increase. Fidson Healthcare followed with N9.97bn, while May & Baker raised its spending by 102 per cent to N2.04bn.
Neimeth also increased its investment to N541m from N69m, while Morrison Industries recorded N14m in capital expenditure.
The spending increase comes amid efforts to strengthen domestic medicine production. NAFDAC’s 5+5 policy encourages manufacturers to establish local facilities or partner with qualified Nigerian producers to reduce dependence on imported drugs.
According to NAFDAC, 20 new pharmaceutical facilities had been completed by May 2026, while another 88 were under construction.
However, manufacturers still face high financing costs, imported raw material expenses and infrastructure challenges.
The success of their investments will depend on how quickly new facilities become operational and generate sustainable revenue.
Source: BusinessDay








